Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mounika Boppana"'
Autor:
Mounika Boppana
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/159fe1f7a818466a87cd9d26d444297b
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 296-299 (2020)
Externí odkaz:
https://doaj.org/article/b077f70c821346209658e083351135e8
Autor:
Mounika Boppana
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 270-272 (2020)
Externí odkaz:
https://doaj.org/article/23ccb8853d2d444fbe7b52d4e226d0b5
Autor:
Nikhil Pande, Omshree Shetty, Mounika Boppana, Anant Ramaswamy, Avanish Saklani, Nitin Shetty, Vikas Ostwal
Publikováno v:
South Asian Journal of Cancer, Vol 8, Iss 1, Pp 51-64 (2019)
Externí odkaz:
https://doaj.org/article/4df1a2bf734a4dd389488714039a6810
Autor:
Mounika Boppana, Chakor Sunil Vora
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 2, Iss 2, Pp 209-211 (2019)
Externí odkaz:
https://doaj.org/article/1eaaedb971d94c7787844db292db2e17
Autor:
Mounika Boppana
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 3, Pp 666-667 (2020)
Externí odkaz:
https://doaj.org/article/bc94868e67564e8982cf0b648b064697
Autor:
Vikas Ostwal, Nikhil Pande, Avanish Saklani, Omshree Shetty, Nitin Shetty, Mounika Boppana, Anant Ramaswamy
Publikováno v:
South Asian Journal of Cancer, Vol 8, Iss 1, Pp 51-64 (2019)
South Asian Journal of Cancer
South Asian Journal of Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba67a4827b45e6d983f3ac4b038bad05
http://journal.sajc.org/article.asp?issn=2278-330X
http://journal.sajc.org/article.asp?issn=2278-330X
Autor:
Rahul Krishnatry, Sujay Srinivas, Tejpal Gupta, Nandini Menon, Mounika Boppana, Vijay Patil, Rakesh Jalali, Dilip Harindran Vallathol, Amit Janu, Gunjesh Kumar, Hollis Dsouza, Annu Rajpurohit, Abhishek Mahajan, Abhishek Chatterjee
Publikováno v:
ecancermedicalscience
Background Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b41f80a6930dce8bfe273bd79705b483
https://pubmed.ncbi.nlm.nih.gov/33680080
https://pubmed.ncbi.nlm.nih.gov/33680080
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 296-299 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353ab1b5dc047292279731d948326a75
https://doi.org/10.4103/crst.crst_150_20
https://doi.org/10.4103/crst.crst_150_20
BACKGROUND: Optimal management of recurrent high grade gliomas continues to be challenging, with Bevacizumab as one of the modalities increasingly used in the last few years. The current audit looks at the pattern of use and its results from a major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce6072bf708f229b90d3ef24484ce230
https://europepmc.org/articles/PMC5463884/
https://europepmc.org/articles/PMC5463884/
